|
|
|
|
|
|
|
14.10.26 - 12:09
|
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its common stock at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Verastem Oncology, are expected to be approximately $250 million. The offering is expected to close on or about October 15, 2026 subject to satisfaction of customary...
|
|
|
14.10.26 - 12:03
|
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan (Business Wire)
|
|
|
Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem's commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class investigational oral KRAS G12D (ON/OFF) inhibitor
Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and member of Verastem's Board of DirectorsBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company's Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and continue to serve on the Company's Board of Directors and as an advisor to the Company.
M...
|
|
|
|
|
05.10.26 - 22:03
|
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price equal to $7.90, the closing price of Verastem Oncology's common stock as reported by Nasdaq on October 1, 2026. A total of 380,500 RSUs granted to the 24 new employees and the stock options to purchase 50,000 shares of common stock granted to one new employee will vest at a rate of 25% on the one-year anniversary of each employee's date of hire, with the remaining shares vesting quarterly over the next three ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.07.26 - 13:33
|
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on Thursday, August 6, 2026, at 4:30 pm ET.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical sig...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
